Pre-clinical Services
Home 
Solutions Discovery
Pre-clinical Services
Home Solutions Discovery
Bridging Discovery and Clinical Success
At PI Health Sciences, we offer end-to-end preclinical services designed to optimize the transition from discovery to clinical proof-of-concept. Leveraging our deep expertise in preclinical development, biomarker validation, pharmacokinetics (PK), and translational strategies, we deliver high-quality, data-driven solutions that accelerate preclinical drug development and enhance clinical outcomes.
Our Preclinical Development Model
Operation Strategy:
-
Programs guided by stage-gate criteria developed by key opinion leaders to maximize success in achieving clinical proof-of-concept.
-
Strategic collaborations with external vendors to develop robust human pharmacokinetic (PK) prediction and human clearance (CL) projection strategies which are core aspects of effective preclinical development services.
-
Seamless integration of patient-derived tissue analysis through partnerships with local medical centers, enabling biomarker validation and disease modeling within our preclinical services framework.
Scientific Excellence:
-
Biomarker Validation: Comprehensive methodologies, including ELISA, flow cytometry, next-generation sequencing, and western blotting, essential for any high-quality preclinical drug development program.
-
PK & Dose Prediction: Accurate First-in-Human (FIH) dose projections using in silico modeling and pharmacokinetic-guided approaches, a critical aspect of our preclinical development services.
-
Test Systems: Access to a wide range of biological samples such as peripheral whole blood, disease organs, liquid biopsies, and synovial fluid to support biomarker analysis and preclinical testing.
Communication & Collaboration:
-
Transparent data sharing and frequent updates to align on project goals and streamline preclinical development.
-
Close collaboration with global experts to refine translational strategies and enhance the success of your preclinical drug development efforts.
-
A unified team culture built with our clients to foster long-term success in delivering innovative preclinical services.
Why Partner With Us?
End-to-End Integration
From biomarker validation to FIH dose prediction, our preclinical development services are built to support the full drug development cycle.
Expert Team
Experienced scientists and industry leaders in preclinical development and translational research.
Regulatory Insight
Strategic alignment with global regulatory requirements, integrated early in our preclinical drug development process.
Scientific Rigor
High-quality, actionable data supported by validated methodologies across all phases of preclinical services.
Collaborative Mindset
A client-first approach with flexible, science-driven execution.
Facilities & Capabilities
Biomarker Analysis
Soluble biomarkers (ELISA), cell-based biomarkers (FACS, Western Blot), and gene expression profiling (RT-PCR) included in our specialized preclinical development services.
h-PK Prediction
Advanced modeling to assess human clearance, bioavailability, and drug exposure-response, critical to safe and effective preclinical drug development.
Test Systems
Broad access to ex vivo and patient-derived samples enables deeper insights for translational research.
Cutting-Edge Methodologies
Flow cytometry for tumor-infiltrating lymphocyte (TIL) analysis and other tools essential for next-gen preclinical services.
Contact Us
Partner with PI Health Sciences to achieve success in your preclinical studies. Contact us today to learn how our preclinical development services can accelerate your journey from discovery to the clinic.